The firm will use the funds to support clinical trials of its ATR inhibitor alnodesertib and its pol theta inhibitor ART6043.

How luxury doomsday bunkers turned into a billionaire status symbol ...

Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in ATM-negative patients for Artios’ potential ...

Artios Pharma collected $115 million from an oversubscribed series D that will support its growing ambitions for its pipeline ...

Numerous scientific studies suggest that making small, practical lifestyle changes can significantly extend lifespan. Daily ...

At the University of Miami Patti and Allan Herbert Business School (Miami Herbert), we prepare students to lead with purpose ...

One student said, “It’s a great project and I was impressed with it, especially coming from a four-year undergraduate ...

New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and ...

In 2017, there were 7,270 untested sexual assault kits in law enforcement agencies across Oklahoma. Survivors and law ...

A multidisciplinary team of researchers has combined deep botanical knowledge with powerful genomic technology to decode and mine the DNA of non-flowering seed plants and uncover genes that evolved to ...

Tasmania’s salmon industry is preparing to roll out a “new generation” of selectively bred fish it says are designed to ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Q3 2025 Earnings Call Transcript November 12, 2025 Acurx Pharmaceuticals, Inc.